In the lychee forests of Lingnan, well‑known varieties such as Gua Lü, Nuomici, Feizixiao, and Xianjinfeng captivate countless palates with their unique flavors. Meanwhile, in the cell culture dishes and shake flasks of Canton Biologics' laboratories, star cell lines such as CHOZen® (CHO‑K1), CHOFlow®, and GEX® serve as “trusted assistants” in large‑molecule biologic drug development, thanks to their outstanding expression performance. Though seemingly unrelated, these two worlds actually share fascinating parallels in characteristics, advantages, and applications. Today, let us embark on this delightful journey that bridges the tip of the tongue and the microscopic realm!

Monoclonal antibody (mAb) drugs have developed rapidly in recent years, but their long R&D cycles and high costs limit patient access. mAb biosimilars have similar safety and efficacy profiles to the reference product. The development of a biosimilar follows a stepwise approach, including quality similarity, non‑clinical similarity, and clinical similarity studies. This stepwise process reduces uncertainty in clinical studies, increases the success rate of drug development, and improves patient access. Therefore, many biotech companies consider mAb biosimilars a key R&D focus. Quality attribute analysis of the reference product and similarity studies of the candidate drug are the foundation of biosimilar development and provide an important basis for clinical study design.